Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Evofem, a biotechnology company focused on the development and commercialization of women's health products, announced today that it met with representatives of the U.S. Food and Drug Administration ("FDA") in a Pre-IND (Investigational New Drug) meeting for its lead product, Amphora to be evaluated for the prevention of recurrence of Bacterial Vaginosis (BV). Research suggests Amphora, a vaginally delivered topical gel, works through a novel mechanism of action against several bacterial and viral organisms. As a result of this meeting, Evofem will be developing a formal research protocol to begin clinical studies.
Saundra Pelletier, Chief Executive Officer of Evofem, said, "I am pleased with the guidance we received and the clarification of the work necessary to file an Investigational New Drug Application. This area of development is consistent with our platform of finding and developing promising healthcare solutions that address unmet needs for women worldwide."
A New Drug Application for Amphora as a non-hormonal, vaginal gel contraceptive was accepted by the United States Food and Drug Administration (FDA) in July of 2015.
About Evofem
Evofem Holdings, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem Holdings, Inc. has two lead product candidates: Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
About Amphora
Amphora is a non-hormonal vaginal gel. In addition to the regulatory filing for approval as a contraceptive, Amphora is being investigated for microbicidal properties to develop a potential multipurpose prevention technology. Amphora works by restoring the vaginal pH levels to those consistent with a healthy vaginal environment.
CONTACT: Media Inquiries
Nicole Beckstrand
[email protected]
858.550.1900 ext. 250
